

Status: Effectivity information can only be shown for content published to the website.

Update information can only be shown for content published to the website.

Marbofloxacin Injection

Details for the public consultation of this monograph are as follows:

EAG/Panel/Working Party	Anti-Infective Medicines
Contact Details	sarah.bowles@mhra.gov.uk kajetan.rakowski2@mhra.gov.uk oliver.waddington@mhra.gov.uk
Deadline for Comment	31 st December 2024
Target Publication Date (subject to change)	BP 2026
Notes	New monograph If limits are too restrictive, please provide batch/stability data to demonstrate that an increase is required.

Action and use

Fluoroquinolone antibacterial.

DEFINITION

Marbofloxacin Injection is a sterile solution of Marbofloxacin in Water for Injections.

The injection complies with the requirements stated under [Parenteral Preparations](#) and with the following requirements.

Content of marbofloxacin, $C_{17}H_{19}FN_4O_4$

95.0 to 105.0% of the stated amount.

IDENTIFICATION

In the Assay, record the UV spectrum of the principal peak in the chromatograms obtained with solutions (1) and (2) with a diode array detector in the range of 220 to 400 nm.

The UV spectrum of the principal peak in the chromatogram obtained with solution (1) is concordant with that of the peak in the chromatogram obtained with solution (2);

the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak in the chromatogram obtained with solution (2).

TESTS

Related substances

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions protected from light.

Solution A 0.27% w/v solution of [sodium dihydrogen phosphate](#) containing 0.35% w/v of [sodium octanesulfonate](#), adjusted to pH 2.5 with [orthophosphoric acid](#).

Solution B 23 volumes of [methanol](#) and 77 volumes of [water](#).

- (1) Dilute the injection, if necessary, in sufficient volume of solution B to give a 0.1% w/v solution of Marbofloxacin with solution B.
- (2) Dilute 1 volume of solution (1) to 50 volumes with solution B. Further dilute 1 volume to 10 volumes with solution B.
- (3) Dissolve 1 vial of [marbofloxacin impurity mixture A EPCRS](#) in 1 mL of solution (1).
- (4) Dilute 1 volume of solution (2) to 2 volumes with solution B.

CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (15 cm × 4.6 mm) packed with [end-capped polar-embedded octadecylsilyl amorphous organosilica polymer for chromatography](#) (3.5 µm) (X-Terra Shield RP18 is suitable).
- (b) Use isocratic elution and the mobile phase described below.
- (c) Use a flow rate of 1.2 mL per minute.
- (d) Use a column temperature of 40°.
- (e) Use a detection wavelength of 315 nm.
- (f) Inject 10 µL of each solution.
- (g) Allow the chromatography to proceed for 2.5 times the retention time of marbofloxacin.

MOBILE PHASE

5 volumes of [glacial acetic acid](#), 230 volumes of [methanol](#) and 770 volumes of solution A.

When the chromatograms are recorded under the prescribed conditions, the relative retention times with reference to marbofloxacin (retention time about 28minutes) are: impurity C = about 0.9; impurity D = about 1.3; impurity E = about 1.5.

SYSTEM SUITABILITY

The test is not valid unless:

in the chromatogram obtained with solution (2), the [resolution](#) between impurity C and marbofloxacin is at least 1.5 and the [resolution](#) between marbofloxacin and impurity D is at least 4.0.

in the chromatogram obtained with solution (4), the [signal to noise ratio](#) of the peak due to marbofloxacin is at least 30.

LIMITS

Identify any peak corresponding to impurity E in the chromatogram obtained with solution (1), using the chromatogram obtained with solution (3), and multiply the area of this peak by a correction factor of 1.5.

In the chromatogram obtained with solution (1):

the area of any peak due to impurities C, D or E are not greater than the area of the principal peak in the chromatogram obtained with solution (2) (2%);

the area of any other secondary peaks is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (2%);

the sum of the areas of all secondary peaks is not greater than 2.5 times the area of the principal peak in the chromatogram obtained with solution (2) (3%).

Disregard any peaks with an area less than the area of the principal peak in the chromatogram obtained with solution (4) (0.1%).

ASSAY

Carry out the method for liquid chromatography, Appendix III D, using the following solutions protected from light.

Solution B 23 volumes of methanol and 77 volumes of water.

- (1) Dilute the injection, if necessary, in sufficient volume of solution B to give a 0.01% w/v solution of Marbofloxacin.
- (2) 0.01% w/v of marbofloxacin BPCRS in solution B.
- (3) Dissolve 1 vial of marbofloxacin impurity mixture A EPCRS in 1 mL of solution (1).

CHROMATOGRAPHIC CONDITIONS

The chromatographic conditions described under Related substances may be used.

SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the resolution between impurity C and marbofloxacin is at least 1.5 and the resolution between marbofloxacin and impurity D is at least 4.0.

DETERMINATION OF CONTENT

Calculate the content of $C_{17}H_{19}FN_4O_4$ in the injection from the chromatograms obtained and using the declared content of $C_{17}H_{19}FN_4O_4$ in marbofloxacin BPCRS.

STORAGE

Marbofloxacin Injection should be kept in a sterile, airtight, tamper-evident container and protected from light.

IMPURITIES

The impurities limited by the requirements of this monograph include those listed under [*Marbofloxacin*](#).

DRAFT MONOGRAPH
SUBJECT TO CHANGE